Small Biotech Companies Could Get Faster USPTO Review Of COVID-19 Patent Applications
Executive Summary
Pilot program aims to examine applications for COVID-19 products subject to approval by FDA within 6 to 12 months; the prioritized examination is available solely for small entities and would save them $2,000.
You may also be interested in...
PTO Offers Faster Review Of Patent Applications, For A $4,000 Fee
The U.S. Patent and Trademark Office is giving patent applicants the chance to get their applications processed within 12 months of submission for an additional fee of $4,000.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.